Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced that it will present new in vivo proof-of-concept data from its ATAC (ASGPR Targeting Chimera) degrader platform at two upcoming drug discovery conferences. Kevin Lumb, DPhil, VP Biology, will present at the Discovery on Target Conference being held October 17-20, 2022. Effie Tozzo, PhD, Chief Scientific Officer, will present at the 5^th Annual Targeted Protein Degradation Summit being held October 25-28, 2022.

“ATACs offer a promising new approach to protein degradation with the potential to expand the reach of this modality to pathogenic targets outside the cell,” commented Dr. Tozzo. “We are excited to share results from our translational PK/PD studies successfully demonstrating in vivo proof-of-concept for ATAC degraders.”

Data highlights include:

• In vivo pharmacokinetic and pharmacodynamic data from rodent studies with ATACs targeting Immunoglobulin G (IgG), an abundant extracellular protein
• In vivo data showing target protein endocytosis via ASGPR in rat hepatocytes and endolysosomal localization and degradation
• Rapid and robust in vivo protein degradation using ATACs that employ Avilar’s proprietary high-affinity, small molecule ASGPR ligands in a monovalent format
• In vitro and in vivo data demonstrating the potential for ATACs to selectively degrade specific protein subclasses

Conference presentation details are as follows:

Title: Targeted Degradation of Extracellular Proteins with ATACs (ASGPR-Targeting Chimeras)

Session: Emerging Degrader Modalities

Presenter: Kevin Lumb, DPhil, Vice President, Biology, Avilar Therapeutics

Date and Time: Wednesday, October 19, 8 a.m. ET

Title: Extracellular Protein Targeted Degradation with Novel ATACs (ASGPR Targeting Chimeras)

Session: Spotlighting Emerging Modalities Targeting Extracellular Proteins and Cell Therapy

Presenter: Effie Tozzo, PhD, Chief Scientific Officer, Avilar Therapeutics

Date and Time: Friday, October 28, 11 a.m. ET

The presentations will be available on the Avilar website following the respective conferences.

About Avilar Therapeutics

Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and is based in Waltham, MA. For more information, please visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005395/en/